-
Je něco špatně v tomto záznamu ?
Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines
VHJ. van der Velden, I. Dombrink, J. Alten, G. Cazzaniga, E. Clappier, D. Drandi, C. Eckert, E. Fronkova, J. Hancock, M. Kotrova, R. Kraemer, M. Montonen, H. Pfeifer, C. Pott, T. Raff, H. Trautmann, H. Cavé, BW. Schäfer, JJM. van Dongen, J. Trka,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní lymfatická leukemie genetika diagnóza MeSH
- genová přestavba MeSH
- geny pro imunoglobuliny MeSH
- kvantitativní polymerázová řetězová reakce metody normy MeSH
- lidé MeSH
- reziduální nádor * genetika diagnóza MeSH
- směrnice pro lékařskou praxi jako téma normy MeSH
- zajištění kvality zdravotní péče MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Minimal/measurable residual disease (MRD) diagnostics using real-time quantitative PCR analysis of rearranged immunoglobulin and T-cell receptor gene rearrangements are nowadays implemented in most treatment protocols for patients with acute lymphoblastic leukemia (ALL). Within the EuroMRD Consortium, we aim to provide comparable, high-quality MRD diagnostics, allowing appropriate risk-group classification for patients and inter-protocol comparisons. To this end, we set up a quality assessment scheme, that was gradually optimized and updated over the last 20 years, and that now includes participants from around 70 laboratories worldwide. We here describe the design and analysis of our quality assessment scheme. In addition, we here report revised data interpretation guidelines, based on our newly generated data and extensive discussions between experts. The main novelty is the partial re-definition of the "positive below quantitative range" category by two new categories, "MRD low positive, below quantitative range" and "MRD of uncertain significance". The quality assessment program and revised guidelines will ensure reproducible and accurate MRD data for ALL patients. Within the Consortium, similar programs and guidelines have been introduced for other lymphoid diseases (e.g., B-cell lymphoma), for new technological platforms (e.g., digital droplet PCR or Next-Generation Sequencing), and for other patient-specific MRD PCR-based targets (e.g., fusion genes).
Bristol MRD Group Bristol Genetics Laboratory Southmead Hospital Bristol UK
Centro Tettamanti Fondazione IRCCS San Gerardo dei Tintori Monza Italy
Department of Genetics University Hospital Robert Debré Paris France
Department of Hematology University Hospital Frankfurt Frankfurt Germany
Department of Immunology LUMC Leiden The Netherlands
Department of Internal Medicine 2 University Hospital Schleswig Holstein Kiel Germany
Department of Pediatric Oncology and Hematology Charité Universitätsmedizin Berlin Berlin Germany
Department of Pediatrics University Hospital of Schleswig Holstein Campus Kiel Kiel Germany
European Scientific foundation for Laboratory Hemato Oncology Zutphen The Netherlands
German Cancer Consortium Heidelberg Germany
Hematology Laboratory Saint Louis Hospital Paris Cité University Paris France
Military Medical City Hospital Doha Qatar
School of Medicine University of Milano Bicocca Monza Italy
Tyks Laboratories Genomics Department Turku University Hospital Turku Finland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013633
- 003
- CZ-PrNML
- 005
- 20240905133508.0
- 007
- ta
- 008
- 240725s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02272-0 $2 doi
- 035 __
- $a (PubMed)38744919
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a van der Velden, Vincent H J $u Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. v.h.j.vandervelden@erasmusmc.nl $1 https://orcid.org/0000000194573763
- 245 10
- $a Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines / $c VHJ. van der Velden, I. Dombrink, J. Alten, G. Cazzaniga, E. Clappier, D. Drandi, C. Eckert, E. Fronkova, J. Hancock, M. Kotrova, R. Kraemer, M. Montonen, H. Pfeifer, C. Pott, T. Raff, H. Trautmann, H. Cavé, BW. Schäfer, JJM. van Dongen, J. Trka, M. Brüggemann, EuroMRD Consortium
- 520 9_
- $a Minimal/measurable residual disease (MRD) diagnostics using real-time quantitative PCR analysis of rearranged immunoglobulin and T-cell receptor gene rearrangements are nowadays implemented in most treatment protocols for patients with acute lymphoblastic leukemia (ALL). Within the EuroMRD Consortium, we aim to provide comparable, high-quality MRD diagnostics, allowing appropriate risk-group classification for patients and inter-protocol comparisons. To this end, we set up a quality assessment scheme, that was gradually optimized and updated over the last 20 years, and that now includes participants from around 70 laboratories worldwide. We here describe the design and analysis of our quality assessment scheme. In addition, we here report revised data interpretation guidelines, based on our newly generated data and extensive discussions between experts. The main novelty is the partial re-definition of the "positive below quantitative range" category by two new categories, "MRD low positive, below quantitative range" and "MRD of uncertain significance". The quality assessment program and revised guidelines will ensure reproducible and accurate MRD data for ALL patients. Within the Consortium, similar programs and guidelines have been introduced for other lymphoid diseases (e.g., B-cell lymphoma), for new technological platforms (e.g., digital droplet PCR or Next-Generation Sequencing), and for other patient-specific MRD PCR-based targets (e.g., fusion genes).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a reziduální nádor $x genetika $x diagnóza $7 D018365
- 650 _2
- $a akutní lymfatická leukemie $x genetika $x diagnóza $7 D054198
- 650 _2
- $a genová přestavba $7 D015321
- 650 _2
- $a zajištění kvality zdravotní péče $7 D011785
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $x normy $7 D017410
- 650 _2
- $a geny pro imunoglobuliny $7 D005803
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $x metody $x normy $7 D060888
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dombrink, Isabel $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Alten, Julia $u Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany
- 700 1_
- $a Cazzaniga, Giovanni $u Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy $u School of Medicine, University of Milano-Bicocca, Monza, Italy
- 700 1_
- $a Clappier, Emmanuelle $u Hematology Laboratory, Saint-Louis Hospital, Paris Cité University, Paris, France $u Université Paris-Cité, Paris, France
- 700 1_
- $a Drandi, Daniela $u Department of Molecular Biotechnology and health sciences, Hematology Division, University of Torino, Torino, Italy
- 700 1_
- $a Eckert, Cornelia $u Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany $u German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
- 700 1_
- $a Fronkova, Eva $u CLIP, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000269008145 $7 xx0105058
- 700 1_
- $a Hancock, Jeremy $u Bristol MRD Group, Bristol Genetics Laboratory, Southmead Hospital, Bristol, UK
- 700 1_
- $a Kotrova, Michaela $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany $1 https://orcid.org/0000000153941072 $7 xx0209776
- 700 1_
- $a Kraemer, Rebekka $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Montonen, Mirkka $u Tyks Laboratories, Genomics Department, Turku University Hospital, Turku, Finland
- 700 1_
- $a Pfeifer, Heike $u Department of Hematology, University Hospital Frankfurt, Frankfurt, Germany
- 700 1_
- $a Pott, Christiane $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany $1 https://orcid.org/0009000592608340
- 700 1_
- $a Raff, Thorsten $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany $u Military Medical City Hospital, Doha, Qatar
- 700 1_
- $a Trautmann, Heiko $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany $1 https://orcid.org/0000000290004747
- 700 1_
- $a Cavé, Hélène $u Hematology Laboratory, Saint-Louis Hospital, Paris Cité University, Paris, France $u Department of Genetics, University Hospital Robert Debré, Paris, France
- 700 1_
- $a Schäfer, Beat W $u University Children's Hospital, Zurich, Switzerland $1 https://orcid.org/0000000159882915
- 700 1_
- $a van Dongen, Jacques J M $u Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca, Salamanca, Spain $u European Scientific foundation for Laboratory Hemato Oncology (ESLHO), Zutphen, The Netherlands $u Department of Immunology, LUMC, Leiden, The Netherlands $1 https://orcid.org/0000000236507087
- 700 1_
- $a Trka, Jan $u CLIP, Department of Pediatric Hematology and Oncology, Second Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000295278608 $7 xx0036261
- 700 1_
- $a Brüggemann, Monika $u Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany
- 710 2_
- $a EuroMRD Consortium
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 6 (2024), s. 1315-1322
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38744919 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133502 $b ABA008
- 999 __
- $a ok $b bmc $g 2143434 $s 1225499
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 6 $d 1315-1322 $e 20240514 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20240725
